PhRMA Promotes Cluster Concept In Japan Reform Wish List
Holistic Changes Needed, US Group Says
US industry association promotes an exchanges with Japan on bioclusters, while continuing to push for holistic debate on reforms to the country’s national healthcare system and changes to reimbursement pricing it sees as supporting innovation.
You may also be interested in...
In the last 10 years, the Asia Pacific region has become a hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally in 2021, a new infographic analysis by Citeline's Trialtrove shows.
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.